NCT03254654View on ClinicalTrials.gov

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

August 16, 2017

Primary Completion Date

August 1, 2021

Study Completion Date

August 1, 2021

Conditions
Advanced Triple-Negative Breast Cancer
Interventions
DRUG

Vinorelbine

Experimental: 20 mg/m2, D6, D13, D20 Active Comparator: 25 mg/m2, D1, D8, D15

DRUG

Apatinib

250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2.

Trial Locations (1)

200032

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT03254654 - Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer | Biotech Hunter | Biotech Hunter